(Q38155277)

29 August 2017

title

Metabolic disease in HIV infection (English)

1 reference

29 August 2017

1 reference

Jordan E Lake

1

1 reference

29 August 2017

Judith S Currier

series ordinal

2

1 reference

29 August 2017

publication date

1 November 2013

1 reference

Lancet Infectious Diseases

29 August 2017

published in

1 reference

29 August 2017

volume

13

1 reference

29 August 2017

issue

11

1 reference

29 August 2017

page(s)

964-975

1 reference

LMNA mutations induce a non-inflammatory fibrosis and a brown fat-like dystrophy of enlarged cervical adipose tissue

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Deiodinase 2 expression is increased in dorsocervical fat of patients with HIV-associated lipohypertrophy syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Brown fat activity is not apparent in subjects with HIV lipodystrophy and increased resting energy expenditure

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Increased FDG uptake in association with reduced extremity fat in HIV patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Comparison of dorsocervical with abdominal subcutaneous adipose tissue in patients with and without antiretroviral therapy-associated lipodystrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Mitochondrial damage in adipose tissue of untreated HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Adipogenic/Lipid, Inflammatory, and Mitochondrial Parameters in Subcutaneous Adipose Tissue of Untreated HIV-1–Infected Long-Term Nonprogressors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Differentially altered molecular signature of visceral adipose tissue in HIV-1-associated lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Evidence for a shift to anaerobic metabolism in adipose tissue in efavirenz-containing regimens for HIV with different nucleoside backbones

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

HIV infection and antiretroviral therapy have divergent effects on mitochondria in adipose tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Adipose tissue biology and HIV-infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Switching antiretroviral therapy to minimize metabolic complications

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-γ-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Autologous fat grafting and injectable dermal fillers for human immunodeficiency virus-associated facial lipodystrophy: a comparison of safety, efficacy, and long-term treatment outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Infectious complications of Bio-Alcamid filler used for HIV-related facial lipoatrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Minimal effects of Darunavir on adipocyte differentiation and metabolism in 3T3-L1 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

The protease inhibitor atazanavir triggers autophagy and mitophagy in human preadipocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Body composition changes after switching from protease inhibitors to raltegravir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Neutral actions of Raltegravir on adipogenesis, glucose metabolism and lipolysis in 3T3-L1 adipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Maraviroc reduces cytokine expression and secretion in human adipose cells without altering adipogenic differentiation.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Growth hormone and HIV infection: contribution to disease manifestations and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Benefits of leptin therapy in HIV patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Adipokines in the HIV/HAART-associated lipodystrophy syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

A pilot study of telmisartan for visceral adiposity in HIV infection: the metabolic abnormalities, telmisartan, and HIV infection (MATH) trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Hypertension and obesity in adults living in a high HIV prevalence rural area in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Multimorbidity patterns in HIV-infected patients: the role of obesity in chronic disease clustering

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Prevalence of obesity and cardiovascular risk in patients with HIV/AIDS in Porto Alegre, Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Echocardiographic abnormalities and associated factors in a cohort of asymptomatic HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

HIV infection and obesity: where did all the wasting go?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

A comparison of factors associated with prevalent diabetes mellitus among HIV-Infected antiretroviral-naive individuals versus individuals in the National Health and Nutritional Examination Survey cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Association of increased upper trunk and decreased leg fat with 2-h glucose in control and HIV-infected persons

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Leptin and adiponectin, but not IL18, are related with insulin resistance in treated HIV-1-infected patients with lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

The role of adipokines in relation to HIV lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Molecular mechanisms for insulin resistance in treated HIV-infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Reduced levels of serum FGF19 and impaired expression of receptors for endocrine FGFs in adipose tissue from HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Understanding diabetes in patients with HIV/AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Metformin: an old but still the best treatment for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

PPAR- γ agonist in treatment of diabetes: cardiovascular safety considerations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Carotid intima media thickness, inflammatory markers, and endothelial activation markers in HIV Patients with lipoatrophy increased at 48 weeks regardless of use of rosiglitazone or placebo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Differential Effects of Rosiglitazone and Metformin on Postprandial Lipemia in Patients With HIV-Lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Antiretroviral therapy adherence and drug–drug interactions in the aging HIV population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

A study of fatty acid binding protein 4 in HIV-1 infection and in combination antiretroviral therapy-related metabolic disturbances and lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 r

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Maraviroc Can Improve Lipid Profiles in Dyslipidemic Patients with HIV: Results from the MERIT Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Abacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Effect of specific ART drugs on lipid changes and the need for lipid management in children with HIV

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Lipid metabolism in treated HIV Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

The effects of dietary intervention on HIV dyslipidaemia: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

HIV infection and coronary heart disease: an intersection of epidemics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Cardiovascular complications in children with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Association of C-reactive protein and HIV infection with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Microbial translocation is a cause of systemic immune activation in chronic HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Plasma levels of soluble CD14 independently predict mortality in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Arterial inflammation in patients with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Relationship between microbial translocation and endothelial function in HIV infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Are monocytes the canary in the coal mine for HIV-related atherosclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Inflammation, coagulation and cardiovascular disease in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Elevated D-dimer is independently associated with endothelial dysfunction: a cross-sectional study in HIV-infected adults on antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970271-8

7 January 2021

10.1016/S1473-3099(13)70271-8

Identifiers

DOI

1 reference

29 August 2017

1 reference